Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

The metalloprotease ADAMTS4 generates N-truncated Aβ4-x species and marks oligodendrocytes as a source of amyloidogenic peptides in Alzheimer's disease.

Walter S, Jumpertz T, Hüttenrauch M, Ogorek I, Gerber H, Storck SE, Zampar S, Dimitrov M, Lehmann S, Lepka K, Berndt C, Wiltfang J, Becker-Pauly C, Beher D, Pietrzik CU, Fraering PC, Wirths O, Weggen S.

Acta Neuropathol. 2019 Feb;137(2):239-257. doi: 10.1007/s00401-018-1929-5. Epub 2018 Nov 13.

PMID:
30426203
2.

Generation and characterization of a rabbit monoclonal antibody site-specific for tau O-GlcNAcylated at serine 400.

Cameron A, Giacomozzi B, Joyce J, Gray A, Graham D, Ousson S, Neny M, Beher D, Carlson G, O'Moore J, Shearman M, Hering H.

FEBS Lett. 2013 Nov 15;587(22):3722-8. doi: 10.1016/j.febslet.2013.09.042. Epub 2013 Oct 7.

3.

Alzheimer's disease mutations in APP but not γ-secretase modulators affect epsilon-cleavage-dependent AICD production.

Dimitrov M, Alattia JR, Lemmin T, Lehal R, Fligier A, Houacine J, Hussain I, Radtke F, Dal Peraro M, Beher D, Fraering PC.

Nat Commun. 2013;4:2246. doi: 10.1038/ncomms3246.

PMID:
23907250
4.

Substrate determinants in the C99 juxtamembrane domains differentially affect γ-secretase cleavage specificity and modulator pharmacology.

Ousson S, Saric A, Baguet A, Losberger C, Genoud S, Vilbois F, Permanne B, Hussain I, Beher D.

J Neurochem. 2013 May;125(4):610-9. doi: 10.1111/jnc.12129. Epub 2013 Jan 18.

5.

The role of γ-secretase activating protein (GSAP) and imatinib in the regulation of γ-secretase activity and amyloid-β generation.

Hussain I, Fabrègue J, Anderes L, Ousson S, Borlat F, Eligert V, Berger S, Dimitrov M, Alattia JR, Fraering PC, Beher D.

J Biol Chem. 2013 Jan 25;288(4):2521-31. doi: 10.1074/jbc.M112.370924. Epub 2012 Dec 3.

6.

Development and characterization of a novel membrane assay for full-length BACE-1 at pH 6.0.

Saric A, Brügge Lz, Müller-Pompalla D, Rysiok T, Ousson S, Permanne B, Quattropani A, Busch M, Beher D, Hussain I.

J Biomol Screen. 2013 Mar;18(3):277-85. doi: 10.1177/1087057112462237. Epub 2012 Sep 27.

PMID:
23023105
7.

Discovery of γ-secretase modulators with a novel activity profile by text-based virtual screening.

Zettl H, Ness J, Hähnke V, Beher D, Jumpertz T, Saric A, Baumann K, Pietrzik CU, Bulic B, Schneider G, Weggen S.

ACS Chem Biol. 2012 Sep 21;7(9):1488-95. Epub 2012 Jul 2.

PMID:
22725102
8.
9.

Resveratrol is not a direct activator of SIRT1 enzyme activity.

Beher D, Wu J, Cumine S, Kim KW, Lu SC, Atangan L, Wang M.

Chem Biol Drug Des. 2009 Dec;74(6):619-24. doi: 10.1111/j.1747-0285.2009.00901.x. Epub 2009 Oct 20.

PMID:
19843076
10.
11.

Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling.

Lewis HD, Leveridge M, Strack PR, Haldon CD, O'neil J, Kim H, Madin A, Hannam JC, Look AT, Kohl N, Draetta G, Harrison T, Kerby JA, Shearman MS, Beher D.

Chem Biol. 2007 Feb;14(2):209-19.

12.

Selective modulation of Abeta42 production in Alzheimer's disease: non-steroidal anti-inflammatory drugs and beyond.

Leuchtenberger S, Beher D, Weggen S.

Curr Pharm Des. 2006;12(33):4337-55. Review.

PMID:
17105431
13.

LRRTM3 promotes processing of amyloid-precursor protein by BACE1 and is a positional candidate gene for late-onset Alzheimer's disease.

Majercak J, Ray WJ, Espeseth A, Simon A, Shi XP, Wolffe C, Getty K, Marine S, Stec E, Ferrer M, Strulovici B, Bartz S, Gates A, Xu M, Huang Q, Ma L, Shughrue P, Burchard J, Colussi D, Pietrak B, Kahana J, Beher D, Rosahl T, Shearman M, Hazuda D, Sachs AB, Koblan KS, Seabrook GR, Stone DJ.

Proc Natl Acad Sci U S A. 2006 Nov 21;103(47):17967-72. Epub 2006 Nov 10.

14.

Intra- or intercomplex binding to the gamma-secretase enzyme. A model to differentiate inhibitor classes.

Clarke EE, Churcher I, Ellis S, Wrigley JD, Lewis HD, Harrison T, Shearman MS, Beher D.

J Biol Chem. 2006 Oct 20;281(42):31279-89. Epub 2006 Aug 9.

15.

3-Substituted gem-cyclohexane sulfone based gamma-secretase inhibitors for Alzheimer's disease: conformational analysis and biological activity.

Jelley RA, Elliott J, Gibson KR, Harrison T, Beher D, Clarke EE, Lewis HD, Shearman M, Wrigley JD.

Bioorg Med Chem Lett. 2006 Jul 15;16(14):3839-42. Epub 2006 May 6.

PMID:
16682202
16.

Quantification of Alzheimer pathology in ageing and dementia: age-related accumulation of amyloid-beta(42) peptide in vascular dementia.

Lewis H, Beher D, Cookson N, Oakley A, Piggott M, Morris CM, Jaros E, Perry R, Ince P, Kenny RA, Ballard CG, Shearman MS, Kalaria RN.

Neuropathol Appl Neurobiol. 2006 Apr;32(2):103-18.

PMID:
16599940
17.

The geminal dimethyl analogue of Flurbiprofen as a novel Abeta42 inhibitor and potential Alzheimer's disease modifying agent.

Stock N, Munoz B, Wrigley JD, Shearman MS, Beher D, Peachey J, Williamson TL, Bain G, Chen W, Jiang X, St-Jacques R, Prasit P.

Bioorg Med Chem Lett. 2006 Apr 15;16(8):2219-23. Epub 2006 Feb 7.

PMID:
16455248
18.

C-terminal PAL motif of presenilin and presenilin homologues required for normal active site conformation.

Wang J, Beher D, Nyborg AC, Shearman MS, Golde TE, Goate A.

J Neurochem. 2006 Jan;96(1):218-27. Epub 2005 Nov 23.

19.

4-substituted cyclohexyl sulfones as potent, orally active gamma-secretase inhibitors.

Churcher I, Beher D, Best JD, Castro JL, Clarke EE, Gentry A, Harrison T, Hitzel L, Kay E, Kerrad S, Lewis HD, Morentin-Gutierrez P, Mortishire-Smith R, Oakley PJ, Reilly M, Shaw DE, Shearman MS, Teall MR, Williams S, Wrigley JD.

Bioorg Med Chem Lett. 2006 Jan 15;16(2):280-4. Epub 2005 Nov 3.

PMID:
16275079
20.

Protease inhibitors as potential disease-modifying therapeutics for Alzheimer's disease.

Beher D, Graham SL.

Expert Opin Investig Drugs. 2005 Nov;14(11):1385-409. Review.

PMID:
16255678
21.

Gamma-secretase as a therapeutic target for the treatment of Alzheimer's disease.

Churcher I, Beher D.

Curr Pharm Des. 2005;11(26):3363-82. Review.

PMID:
16250842
22.

Cyclic sulfamide gamma-secretase inhibitors.

Sparey T, Beher D, Best J, Biba M, Castro JL, Clarke E, Hannam J, Harrison T, Lewis H, Madin A, Shearman M, Sohal B, Tsou N, Welch C, Wrigley J.

Bioorg Med Chem Lett. 2005 Oct 1;15(19):4212-6.

PMID:
16054361
23.

Two domains within the first putative transmembrane domain of presenilin 1 differentially influence presenilinase and gamma-secretase activity.

Brunkan AL, Martinez M, Wang J, Walker ES, Beher D, Shearman MS, Goate AM.

J Neurochem. 2005 Sep;94(5):1315-28. Epub 2005 Jul 7.

24.

Determination of guinea-pig cortical gamma-secretase activity ex vivo following the systemic administration of a gamma-secretase inhibitor.

Grimwood S, Hogg J, Jay MT, Lad AM, Lee V, Murray F, Peachey J, Townend T, Vithlani M, Beher D, Shearman MS, Hutson PH.

Neuropharmacology. 2005 Jun;48(7):1002-11.

PMID:
15857627
25.

Functional overexpression of gamma-secretase reveals protease-independent trafficking functions and a critical role of lipids for protease activity.

Wrigley JD, Schurov I, Nunn EJ, Martin AC, Clarke EE, Ellis S, Bonnert TP, Shearman MS, Beher D.

J Biol Chem. 2005 Apr 1;280(13):12523-35. Epub 2004 Dec 21.

26.

A novel series of potent gamma-secretase inhibitors based on a benzobicyclo[4.2.1]nonane core.

Lewis SJ, Smith AL, Neduvelil JG, Stevenson GI, Lindon MJ, Jones AB, Shearman MS, Beher D, Clarke E, Best JD, Peachey JE, Harrison T, Castro JL.

Bioorg Med Chem Lett. 2005 Jan 17;15(2):373-8.

PMID:
15603957
27.

Gamma-secretase complex assembly within the early secretory pathway.

Capell A, Beher D, Prokop S, Steiner H, Kaether C, Shearman MS, Haass C.

J Biol Chem. 2005 Feb 25;280(8):6471-8. Epub 2004 Dec 10.

28.

gamma-Secretase as a target for drug intervention in Alzheimer's disease.

Harrison T, Churcher I, Beher D.

Curr Opin Drug Discov Devel. 2004 Sep;7(5):709-19. Review.

PMID:
15503873
29.

Fatty acids increase presenilin-1 levels and [gamma]-secretase activity in PSwt-1 cells.

Liu Y, Yang L, Conde-Knape K, Beher D, Shearman MS, Shachter NS.

J Lipid Res. 2004 Dec;45(12):2368-76. Epub 2004 Sep 16.

30.

Conserved residues within the putative active site of gamma-secretase differentially influence enzyme activity and inhibitor binding.

Wrigley JD, Nunn EJ, Nyabi O, Clarke EE, Hunt P, Nadin A, De Strooper B, Shearman MS, Beher D.

J Neurochem. 2004 Sep;90(6):1312-20.

31.

Novel aspects of accumulation dynamics and A beta composition in transgenic models of AD.

Lewis HD, Beher D, Smith D, Hewson L, Cookson N, Reynolds DS, Dawson GR, Jiang M, Van der Ploeg LH, Qian S, Rosahl TW, Kalaria RN, Shearman MS.

Neurobiol Aging. 2004 Oct;25(9):1175-85.

PMID:
15312963
32.

Selected non-steroidal anti-inflammatory drugs and their derivatives target gamma-secretase at a novel site. Evidence for an allosteric mechanism.

Beher D, Clarke EE, Wrigley JD, Martin AC, Nadin A, Churcher I, Shearman MS.

J Biol Chem. 2004 Oct 15;279(42):43419-26. Epub 2004 Aug 10.

33.

Disrupted in Schizophrenia 1 and Nudel form a neurodevelopmentally regulated protein complex: implications for schizophrenia and other major neurological disorders.

Brandon NJ, Handford EJ, Schurov I, Rain JC, Pelling M, Duran-Jimeniz B, Camargo LM, Oliver KR, Beher D, Shearman MS, Whiting PJ.

Mol Cell Neurosci. 2004 Jan;25(1):42-55.

PMID:
14962739
34.

In vitro characterization of the presenilin-dependent gamma-secretase complex using a novel affinity ligand.

Beher D, Fricker M, Nadin A, Clarke EE, Wrigley JD, Li YM, Culvenor JG, Masters CL, Harrison T, Shearman MS.

Biochemistry. 2003 Jul 15;42(27):8133-42.

PMID:
12846562
35.

gamma-Secretase inhibitors--from molecular probes to new therapeutics?

Harrison T, Beher D.

Prog Med Chem. 2003;41:99-127. Review. No abstract available.

PMID:
12774692
37.

gamma-Secretase cleavage site specificity differs for intracellular and secretory amyloid beta.

Grimm HS, Beher D, Lichtenthaler SF, Shearman MS, Beyreuther K, Hartmann T.

J Biol Chem. 2003 Apr 11;278(15):13077-85. Epub 2003 Jan 29.

38.

Gamma-secretase inhibition.

Beher D, Shearman MS.

Biochem Soc Trans. 2002 Aug;30(4):534-7. Review.

PMID:
12196131
39.

Generation of C-terminally truncated amyloid-beta peptides is dependent on gamma-secretase activity.

Beher D, Wrigley JD, Owens AP, Shearman MS.

J Neurochem. 2002 Aug;82(3):563-75.

40.

The intramembrane cleavage site of the amyloid precursor protein depends on the length of its transmembrane domain.

Lichtenthaler SF, Beher D, Grimm HS, Wang R, Shearman MS, Masters CL, Beyreuther K.

Proc Natl Acad Sci U S A. 2002 Feb 5;99(3):1365-70. Epub 2002 Jan 22.

41.

Pharmacological knock-down of the presenilin 1 heterodimer by a novel gamma -secretase inhibitor: implications for presenilin biology.

Beher D, Wrigley JD, Nadin A, Evin G, Masters CL, Harrison T, Castro JL, Shearman MS.

J Biol Chem. 2001 Nov 30;276(48):45394-402. Epub 2001 Sep 26.

42.

Homodimerization of amyloid precursor protein and its implication in the amyloidogenic pathway of Alzheimer's disease.

Scheuermann S, Hambsch B, Hesse L, Stumm J, Schmidt C, Beher D, Bayer TA, Beyreuther K, Multhaup G.

J Biol Chem. 2001 Sep 7;276(36):33923-9. Epub 2001 Jul 3.

43.

L-685,458, an aspartyl protease transition state mimic, is a potent inhibitor of amyloid beta-protein precursor gamma-secretase activity.

Shearman MS, Beher D, Clarke EE, Lewis HD, Harrison T, Hunt P, Nadin A, Smith AL, Stevenson G, Castro JL.

Biochemistry. 2000 Aug 1;39(30):8698-704.

PMID:
10913280
44.

Proteolytic fragments of Alzheimer's disease-associated presenilin 1 are present in synaptic organelles and growth cone membranes of rat brain.

Beher D, Elle C, Underwood J, Davis JB, Ward R, Karran E, Masters CL, Beyreuther K, Multhaup G.

J Neurochem. 1999 Apr;72(4):1564-73.

45.

Reactive oxygen species and Alzheimer's disease.

Multhaup G, Ruppert T, Schlicksupp A, Hesse L, Beher D, Masters CL, Beyreuther K.

Biochem Pharmacol. 1997 Sep 1;54(5):533-9. Review.

PMID:
9337068
46.

The amyloid precursor protein of Alzheimer's disease in the reduction of copper(II) to copper(I)

Multhaup G, Schlicksupp A, Hesse L, Beher D, Ruppert T, Masters CL, Beyreuther K.

Science. 1996 Mar 8;271(5254):1406-9.

PMID:
8596911
47.
48.

Regulation of APP expression, biogenesis and metabolism by extracellular matrix and cytokines.

Beyreuther K, Multhaup G, Mönning U, Sandbrink R, Beher D, Hesse L, Small DH, Masters CL.

Ann N Y Acad Sci. 1996 Jan 17;777:74-6. Review.

PMID:
8624129
49.

The beta A4 amyloid precursor protein binding to copper.

Hesse L, Beher D, Masters CL, Multhaup G.

FEBS Lett. 1994 Jul 25;349(1):109-16.

Supplemental Content

Support Center